Immune Checkpoint Inhibitors in Geriatric Oncology

Area of Science:

• Cancer Immunology
• Gerontology
• Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
• Older patients are increasingly treated with ICIs, but trials often lack age-specific data.
• Aging processes, such as cellular senescence, impact immune function and response to ICIs.

Purpose of the Study:

• To provide an updated review of ICIs in cancer immunology and aging.
• To examine how aging affects the immune system's response to ICIs.
• To discuss clinical implications and tools for older cancer patients receiving ICIs.

Main Methods:

• Review of basic science, translational, and clinical discoveries.
• Analysis of recent clinical trial data concerning older adults.
• Discussion of validated tools for risk assessment in elderly patients.

Main Results:

• Aging alters the immune system, potentially affecting ICI efficacy and toxicity.
• Limited data exists on ICI outcomes specifically designed for older populations.
• Clinical tools can help identify older adults at higher risk for treatment complications.

Conclusions:

• Understanding aging's impact on immunity is crucial for optimizing ICI therapy.
• Further research and age-tailored trials are needed for older cancer patients.
• Clinical assessment tools are vital for managing ICI treatment in the elderly.